K2M enters French spinal device market with MESA Deformity Spinal System

K2M, Inc., the largest privately held spinal device company in the world focused on developing innovative solutions for the treatment of complex spinal pathologies and minimally invasive procedures, today announced at the Scoliosis Research Society’s (SRS) 48th Annual Conference in Lyon, France, that it has entered the spinal device market in France. The first surgical case was performed by Dr. Christophe Garin at the Groupement hôpitaux Est., Hopital Femme, Mere, Enfant in Lyon, using the company’s MESA® Deformity Spinal System.

MESA Deformity is a top-loading, low profile spinal system featuring K2M’s Zero-Torque Technology®. The revolutionary design of the Deformity Reduction Jack (Cricket®) coupled with a complete offering of varied screw types, provides surgeons with the ability to accomplish the most difficult correction maneuvers across all planes utilizing unique instrumentation for slow, controlled correction of the spine.

“Our first surgery in France could not be more timely given our attendance at the SRS conference in Lyon this week.  It is also an important market for K2M, as much of the history of spine deformity surgery originated in France,” stated Eric Major, K2M’s President and CEO. “K2M has been, and will continue to be, committed to establishing ourselves as the global leader in providing solutions for complex spinal pathologies.”

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Patient-derived organoids: Transforming cancer research and personalized medicine